See every side of every news story
Published loading...Updated

Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (Sebetralstat)

UNITED STATES, JUL 7 – Ekterly offers faster symptom relief within 1.3 hours and allows a second dose within three hours, improving treatment flexibility for hereditary angioedema patients, analysts say.

  • The FDA approved KalVista Pharmaceuticals' oral pill Ekterly on Monday to treat acute hereditary angioedema attacks in patients aged 12 and older.
  • This approval followed a delayed FDA decision beyond the June 17 deadline and was based on positive Phase III KONFIDENT trial results showing faster symptom relief than placebo.
  • The KONFIDENT trial included 136 patients across 66 sites in 20 countries and demonstrated a median symptom relief time of about 1.6 hours with Ekterly versus 6.7 hours for placebo.
  • KalVista CEO Ben Palleiko called the approval a defining moment that enables patients to treat attacks at onset, while analyst Paul Matteis noted Ekterly's injectable-like efficacy could grow the stable on-demand HAE market.
  • KalVista priced Ekterly at $16,720 per dose and granted commercialization rights for Japan in April 2025, aiming to deliver the first oral, on-demand HAE treatment widely to patients.
Insights by Ground AI
Does this summary seem wrong?

23 Articles

All
Left
Center
9
Right
1
abc12/WJRTabc12/WJRT
+11 Reposted by 11 other sources
Center

Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)

EKTERLY is an FDA-approved oral therapy for the on-demand treatment of hereditary angioedema (HAE)

·Flint, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 90% of the sources are Center
90% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Monday, July 7, 2025.
Sources are mostly out of (0)